VCN Biosciences SL is a privately-owned company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for VCN-01.
Latest news:
-
VCN Biosciences announces initiation of clinical studies of VCN-01 in cancer patient.
> Read more
-
VCN Biosciences' new facilities at Grifols Corporate Offices.
> Read more
-
VCN Biosciences presents its results on chemosensitizing capabilities of VCN-01 in the Seventh International Meeting On Replicating Oncolytic Virus Therapeutics, held in Quebec (Canada).
> Read more
-
VCN Biosciences has secured intellectual property rights in Spain for the hyaluronidase technology included in its lead candidate VCN-01.
> Read more
-
VCN Biosciences at the 2012 Annual Meeting of the European Society of Cell & Gene Therapy in Versailles (France).
> Read more
-
Grifols group enters
VCN Biosciences aquiring equity shares and warrants the development of therapeutic candidates of the company.
> Leer mas > PDF
-
VCN Biosciences is again present at the BIO International Convention in Boston , the largest global event in biotech sector around the world.
> Read more
-
VCN Biosciences exposes to European Medicines Agency and Spanish Medicines Authority its development for VCN-01.
> Read more
